Literature DB >> 27784531

Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled trials and observational studies.

Dominik Mertz1, Shaza A Fadel, Po-Po Lam, Dat Tran, Jocelyn A Srigley, Sandra A Asner, Michelle Science, Stefan P Kuster, Johannes Nemeth, Jennie Johnstone, Justin R Ortiz, Mark Loeb.   

Abstract

Influenza vaccination programmes are assumed to have a herd effect and protect contacts of vaccinated persons from influenza virus infection. We searched MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Global Health and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to March 2014 for studies assessing the protective effect of influenza vaccination vs no vaccination on influenza virus infections in contacts. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using a random-effects model. Of 43,082 screened articles, nine randomised controlled trials (RCTs) and four observational studies were eligible. Among the RCTs, no statistically significant herd effect on the occurrence of influenza in contacts could be found (OR: 0.62; 95% CI: 0.34-1.12). The one RCT conducted in a community setting, however, showed a significant effect (OR: 0.39; 95% CI: 0.26-0.57), as did the observational studies (OR: 0.57; 95% CI: 0.43-0.77). We found only a few studies that quantified the herd effect of vaccination, all studies except one were conducted in children, and the overall evidence was graded as low. The evidence is too limited to conclude in what setting(s) a herd effect may or may not be achieved. This article is copyright of The Authors, 2016.

Entities:  

Keywords:  herd effect; indirect effect; influenza; systematic review; vaccine-preventable diseases; vaccines and immunisation

Mesh:

Substances:

Year:  2016        PMID: 27784531      PMCID: PMC5291154          DOI: 10.2807/1560-7917.ES.2016.21.42.30378

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


Introduction

Influenza is a major cause of morbidity and mortality worldwide [1-3]. Many countries recommend vaccination against influenza to prevent influenza infections, in particular for groups at high risk for complications [4-7]. Some high risk groups, such as young children and elderly persons (commonly defined as those above 65 years of age), experience decreased influenza vaccine effectiveness compared with healthy adults [8,9], complicating influenza prevention strategies. Moreover, because such groups represent a minority of the population at large, the population-wide impact of vaccination of risk groups may be limited [7,10]. Influenza vaccine modelling and ecological studies identifying benefits of herd effect have informed seasonal and pandemic influenza vaccine policies [10,11], herd effect being usually defined as the indirect protection of individuals susceptible to infection when a sufficient proportion of the population is immune to the pathogen. Vaccinating persons most likely to respond to the influenza vaccine and relying on herd effect to reduce the chance of exposure to influenza may protect unvaccinated or high-risk individuals. Herd effect may therefore mitigate the consequences of impaired vaccine response in some high-risk groups [12-14]. The purpose of this systematic review was to summarise the evidence on herd effect from influenza vaccination outside healthcare settings. These data may help to inform public health on influenza vaccine research and policy development.

Methods

All decisions regarding eligibility criteria, search strategy, study selection, assessment of risk for bias, explanation for heterogeneity, data collection and analysis were established before data collection. The protocol was registered with the international prospective register of systematic reviews (PROSPERO) [15] (CRD42014009401) and was reported in accordance with the PRISMA statement [16].

Eligibility criteria and outcomes assessed

Studies assessing the protective effect of influenza vaccination vs no influenza vaccination (either no vaccination, placebo or alternative vaccine) on contacts of any age group in a non-healthcare setting were eligible. The definition of contacts was broad and included anyone in the same community, school or household. Study designs included randomised controlled trials (RCTs) and observational studies with a non-influenza vaccine comparator group. For the latter study type, quasi-experimental (before–after) studies, cohort studies, case–control studies and cross-sectional studies were eligible. Ecological studies and modelling studies were excluded. We also excluded studies conducted within healthcare institutions, such as nursing homes and hospitals, and studies in languages other than English. The primary outcome was influenza in non-vaccinated contacts exposed to persons vaccinated against influenza vs those not vaccinated. Influenza included both laboratory-confirmed influenza (defined by one or more of the following: nucleic acid amplification testing, viral culture, antigen detection, pre-/post-season or acute/convalescent serology) or non-laboratory-defined evidence. Non-laboratory-defined evidence required the presence of influenza-like illness (ILI, as per the study definition) within a period of time when laboratory-confirmed influenza was circulating in the study area. Secondary outcomes included hospitalisation, pneumonia and death.

Search strategy, study selection and data extraction

We searched MEDLINE (since 1950), EMBASE (since 1980), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (since 1982), Global Health (since 1973) and the Cochrane Central Register of Controlled Trials (CENTRAL) up to 7 March 2014. We also searched reference lists of identified articles and those of review articles for eligible studies. Multiple teams of two reviewers independently screened titles and abstracts and, for studies identified by at least one reviewer to be of potential interest, full-text articles were screened. Data from eligible studies were extracted independently by two reviewers using a database. Any disagreement between the reviewers was resolved by consensus or arbitration by a third reviewer. We attempted to contact the first and corresponding author of the original article whenever potentially important information was missing. Assessment of the risk of bias and of the overall quality of evidence was also conducted by two reviewers independently. We used the Cochrane Review Collaboration’s tool [17] to assess the risk of bias for RCTs, and the Newcastle-Ottawa scale (NOS) [18] to assess the quality of observational studies. The overall quality of evidence was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria [19]. Given the small number of studies, no formal assessment of the risk of publication bias could be conducted [20].

Data analysis

We performed meta-analyses of RCTs and observational studies separately. We calculated odds ratios (ORs) and corresponding 95% confidence intervals (CIs) as summary estimates using random-effects modelling (using RevMan 5.3 [21]). We planned a priori to conduct two subgroup analyses. First, we examined herd effect by study setting, comparing the effect in household studies, school-based studies (where the impact on non-vaccinated schoolchildren was measured) and community studies. For community studies, those comparing geographically defined areas with different vaccination strategies were considered. We hypothesised that the closer the contact was to vaccinated persons, the stronger the effect would be. Second, we assessed whether the herd effect of the vaccination in young children (up to 5 years of age) was different from that in older children and teenagers (5–18 years), and in adults. Heterogeneity was evaluated using χ2 and I2 statistics [22]. We considered a χ2 of < 0.10 or an I2 statistic of > 50% to reflect significant heterogeneity. If significant heterogeneity was found, we planned to perform additional subgroup analyses. Our a priori hypotheses to explain heterogeneity beyond the planned subgroup analyses were: laboratory-confirmed vs non-laboratory-confirmed influenza cases, and cases confirmed by nucleic acid amplification testing and viral culture vs cases confirmed by other laboratory methods. We also analysed the predominant circulating type/subtype (influenza A(H3N2) orA(H1N1), and influenza B).

Results

After removing 18,157 duplicates, we screened a total of 43,082 titles and abstracts, reviewed 184 full-text articles and included nine RCTs and four observational studies in our systematic review (Figure 1). Of the 13 RCTs and observational studies, seven were conducted in North America, and two each in Italy and Russia, and one in Malaysia and Hong Kong Special Administrative Region, respectively (Table 1).
Figure 1

Flowchart of included and excluded randomised control trials and observational studies identified in a systematic review of herd effect from influenza vaccination in non-healthcare settings

Table 1

Study characteristics of studies included in a systematic review of herd effect arising from influenza vaccination in non-healthcare settings

First author [source]Study locationStudy periodPredominant influenza virus type or subtypeIntervention groupSettingNumber of vaccineesNumber of contactsaLaboratory confirmation of influenza
Randomised control trials
Gruber [29]United States1985/86BChildren aged 3–18 yearsHousehold133123Yes
Clover [33]United States1986/87A(H1N1)Children aged 3–19 yearsHousehold194177Yes
Rudenkob [23]Russia1989–91A(H3N2)Children aged 7–14 yearsSchool11,071Not availableNo
Hurwitz [13]United States1996/97Influenza BChildren aged 2–5 yearsHousehold127228No
Esposito [34]Italy2000/01H1N1Children aged 0.5–9 yearsHousehold127349No
Principib [24]Italy2001/02Influenza BChildren aged 0.5–5 yearsHousehold3031,098No
Hui [31]Malaysia2005Not reportedAdults aged 18–64 yearsHousehold346362No
Cowling [30]Hong Kong SAR2008/09A(H3N2)Children aged 6–15 yearsHousehold119312Yes
Loeb [12]Canada2009A(H3N2)Children aged 1.5–15 yearsCommunity9472,326Yes
Observational studies (all cohort studies)
Piedra [26]United States1998–2001A(H3N2)Children aged 1.5–18 yearsCommunityca 40,000350,296No
Ghendon [25]Russia2001–03A(H3N2)Children aged 3–17 yearsCommunity87,221158,451No
King [14]United States2004/05A(H3N2)Children aged 5–14 yearsHousehold2,7173,022cNo
Kjos [27]United States2010/11A(H3N2)Children, age unavailableElementary school(5–10 year-olds)1,012937No

  SAR: Special Administrative Region.

a The definition of contacts was broad and included anyone in the same community, school or household.

b The randomised control trial did not report all numerator and denominator data and therefore could not be included in the meta-analysis.

c In this study, the number of contacts was not reported. The number shown is the number of households (3,022) included in the analysis in intervention schools; there were 5,488 households in control schools).

Flowchart of included and excluded randomised control trials and observational studies identified in a systematic review of herd effect from influenza vaccination in non-healthcare settings a Two randomised control trials did not report all numerator and denominator data and therefore could not be included in the meta-analysis. SAR: Special Administrative Region. a The definition of contacts was broad and included anyone in the same community, school or household. b The randomised control trial did not report all numerator and denominator data and therefore could not be included in the meta-analysis. c In this study, the number of contacts was not reported. The number shown is the number of households (3,022) included in the analysis in intervention schools; there were 5,488 households in control schools).

Findings from randomised controlled trials

Of the nine RCTs included, seven were conducted in a household setting, one in a school and one in a community setting (Table 1). The intervention group consisted of children in all but one study. The total sample size of contacts was 4,975, with one study –the largest– not reporting the total number of contacts [23]. A total of six RCTs provided data for the primary analysis comparing influenza-like illness in contacts of vaccinated vs unvaccinated persons (Figure 2). Overall, no statistically significant herd effect was found (OR: 0.62; 95% CI: 0.34–1.12), with significant statistical heterogeneity (I2 = 78%). Only one study, by Loeb et al., assessed contacts for influenza virus infection at community level: vaccination of children reduced the influenza infection rate for the community (OR: 0.39; 95% CI: 0.26–0.57) [12]. In contrast, there was no statistically significant effect in the subgroup of RCTs assessing household contacts (OR: 0.71; 95% CI: 0.34–1.50). No other differences between subgroups were found (p = 0.15 for subgroup differences). There was an 86% reduction in the odds of 5–17 year-old contacts of vaccinated individuals becoming infected as compared with contacts of unvaccinated individuals (OR: 0.14; 95% CI: 0.03–0.70), while no statistically significant differences were found when contacts were less than five years-old or adults. This difference across age groups was not statistically significant (p = 0.26).
Figure 2

Meta-analysis of seven included randomised controlled trials reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated individuals in non-healthcare settings

Meta-analysis of seven included randomised controlled trials reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated individuals in non-healthcare settings CI: confidence interval; df: degrees of freedom; M-H: Mantel-Haenszel. Given the significant amount of statistical heterogeneity in the primary analyses, we conducted additional subgroup analyses. Subgrouping by whether or not influenza was laboratory confirmed did not significantly reduce statistical heterogeneity (p for subgroup differences was 0.06; I2 = 70·8%), with a significant effect on influenza infections in contacts in RCTs with no laboratory confirmation (OR: 0.33; 95% CI: 0.17–0.64; I2 = 43%; n = 2) and no effect in RCTs using laboratory confirmation (OR: 0.87; 95% CI: 0.40–1.89; I2 = 81%; n = 4). Subgrouping by type of laboratory confirmation or by influenza virus type/subtype could not further explain the statistical heterogeneity. Two RCTs provided data on hospitalisation of contacts, with no statistically significant difference seen (OR 0.83; 95% CI: 0.17–4.1). Only the RCT by Loeb et al. [12] reported on mortality and pneumonia in contacts, with no effect of the vaccine on either of these outcomes in community contacts. Because of the limited number of studies reporting these outcomes, no subgroup analyses could be performed. Two other RCTs demonstrated a herd effect of influenza vaccination, but the data provided in the publications did not report the numerators and denominators needed for our meta-analysis, and we were unable to obtain further data or information from the authors. Principi et al. concluded that influenza vaccination significantly reduced the direct and indirect influenza-related costs in healthy children and their unvaccinated family members [24]. Rudenko et al. found that the use of a live attenuated influenza vaccine was associated with a lower rate of influenza-like illness in school staff and non-vaccinated children when comparing schools that had vs schools that did not have an institutional influenza vaccination programme [23].

Findings from observational studies

A total of four observational studies were identified (Table 1). The intervention groups consisted of children in all the studies. Two studies were conducted in a community setting, and one each in the household and school setting. The total sample size of contacts was more than 500,000. The level of analysis was the household, and not the individual person, in one of the studies [14]. Meta-analysis showed a significant reduction of influenza illness in contacts of vaccinated patients (OR 0.57; 95% CI: 0.43–0.77) (Figure 3). Heterogeneity was very high (I2 = 98%); however, the direction of the effect was identical in all studies, only the amount of the effect size varied across studies. No age-specific data were available. When comparing the three study settings, no significant subgroup effect was found (p = 0.85 for subgroup differences). Given that all studies were lacking laboratory confirmation, and all were conducted during influenza A(H3N2)-predominant influenza seasons, no further subgroup analyses could be performed.
Figure 3

Meta-analysis of four included observational studies reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated patients in non-healthcare settings

Meta-analysis of four included observational studies reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated patients in non-healthcare settings CI: confidence interval; df: degrees of freedom; M-H: Mantel-Haenszel. Only Ghendon et al. [25] reported on pneumonia, and found a significant reduction in contacts of influenza vaccinated patients (OR: 0.38; 95% CI: 0.30–0.50). Hospital admission was only reported in one study [14]; showing higher hospital admission rates in contacts of vaccinated persons (OR: 1.92; 95% CI: 1.17–3.14). There were no studies reporting on mortality endpoints.

Risk of bias and grading of evidence

The most common potential risks of bias in the included RCTs were lack of appropriate generation of the randomisation sequence, lack of allocation concealment and lack of blinding of patients and healthcare providers (Table 2). The RCTs scored a mean of 4.3 (range: 2–7) when assessed against seven domains.
Table 2

Risk of bias in nine included randomised controlled trials reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated individuals in non-healthcare settings

First author [source]Risk of bias
Sequence generationAllocation concealmentBlinding of patientsBlinding of healthcare providerBlinding of outcome adjudicatorsIncomplete data addressedSelective reporting
Gruber [29]NKNKLowLowLowLowLow
Clover [33]NKNKLowNKLowLowLow
Rudenko [23]NKNKLowNKLowLowLow
Hurwitz [13]NKNKLowNKNKNKLow
Esposito [34]LowNKLowLowLowLowLow
Principi [24]NKNK HighHighNKLowLow
Hui [31]NKNKHigh High LowLowLow
Cowling [30]LowNK Low LowLowLowLow
Loeb [12]LowLowLowLowLowLowLow
Percentage low risk of biasa331122337889100

NK: not known, as either unclear or not reported.

a The percentage low risk of bias for each domain was calculated by dividing the number of randomised controlled trials (RCTs) at low risk of bias by the total number of RCTs (n = 9).

NK: not known, as either unclear or not reported. a The percentage low risk of bias for each domain was calculated by dividing the number of randomised controlled trials (RCTs) at low risk of bias by the total number of RCTs (n = 9). The observational studies were awarded a mean of 6.25 points of a maximum of nine on the Newcastle-Ottawa scale, i.e. they were in a middle range of risk of bias (7 for Piedra et al. [26] and Ghendon et al. [25], 6 for Kjos [27] and 5 for King et al. [14]). Applying GRADE criteria, we decreased the level of evidence for the primary outcome because of serious limitations in the quality of the studies (i.e. risk of bias in RCTs and observational design in non-RCTs) and inconsistency with significant statistical heterogeneity. Therefore, the overall level of evidence supporting a herd effect of influenza vaccines in preventing influenza virus infection in contacts in non-healthcare settings was considered to be low.

Discussion

We found an overall low level of evidence supporting an indirect or herd effect of influenza vaccination in preventing influenza virus infection in vaccinated persons’ contacts. In all but one study we identified, children were vaccinated. While observational studies showed a significant effect, the summary estimates from RCTs did not show a statistically significant effect. Few data were available on herd effect of influenza vaccination preventing hospital admission, pneumonia and death. Point estimates of four of the six RCTs that reported on the prevention of influenza virus infection in contacts of vaccinated persons pointed towards a potential benefit of vaccination, but no significant effect was found overall. In an RCT by Loeb et al. involving Hutterite communities [12], vaccination of children in an enclosed community significantly reduced influenza infections in contacts. The uptake of influenza vaccination in that RCT, which had a low risk of bias in all domains assessed, was ca 83%. The RCT confirmed the findings from an observational study by Monto et al. that found a similar effect at the population level by vaccinating schoolchildren in one community in Michigan, United States [28]. However, no strong evidence was found in a household setting [29,30]. A possible explanation is that vaccinating only one child per household, as done in the study by Cowling et al., may have been insufficient to have a measurable effect [30]. In the study by Gruber et al., in contrast, all children three years of age and older received the vaccine, but again there was no effect on household contacts. However, the study was limited by the low attack rate and was therefore likely underpowered [29]. Furthermore, the authors argued that the non-vaccinated contacts were likely to be immune to the predominant influenza B strain that circulated in previous years. It is therefore unclear what key factors are needed to achieve a herd effect in the household, particularly given the importance of the broader community as a potential source of infection of the non-vaccinated. Notably, the only study that investigated herd effect of influenza vaccination of adults did find a statistically significant effect [31]. However, this study had significant methodological limitations, including lack of blinding. It should be acknowledged that two studies that both reported a significant herd effect of influenza vaccination could not be included in the meta-analysis because of the lack of detail reported in the published article, and no additional information could be obtained from the authors [23,24]. In contrast to our findings from RCTs, we found evidence of herd effect following influenza vaccination in observational studies, which was corroborated by a recent observational study by Pannaraj et al., who found that unvaccinated children may be protected in schools with vaccination rates approaching 50% [32]. Our extensive screening of over 40,000 studies found very few studies that were designed to measure herd effects of influenza vaccination. One reason for this may be the cost of community influenza surveillance as well as the cost of clinical trials. While modelling studies demonstrate that herd immunity can be achieved by vaccinating young children [10], we are surprised by how few studies with laboratory-confirmed influenza as an outcome support the modelling literature. Moreover, there are very limited data available to estimate herd effect of influenza vaccination programmes. As indirect benefits would increase the cost-effectiveness of these programmes, such data would be highly valuable for vaccine advisory bodies and decision makers evaluating whether to initiate or expand influenza vaccine programmes. Our review highlights the need for more rigorous studies using laboratory-confirmed influenza virus infections as an outcome. Data on a herd effect on outcomes other than influenza virus infection were sparse, due either to outcomes not being measured or to inadequate power to detect a difference. Although the effect of influenza vaccination on mortality has been demonstrated through modelling [10], high-quality studies would better support the ability of influenza vaccination to prevent hospital admissions, pneumonia or death in contacts through herd effect. Strengths of this systematic review include a systematic, protocol-driven and comprehensive review with extensive literature search strategy including RCTs and observational studies. In addition, rigorous assessment of eligibility ensured high reliability of the results. All subgroup analyses were defined a priori. A rigorous use of the GRADE approach ensured a transparent and comprehensive approach to evaluate overall quality of the studies. An important limitation, however, was the presence of statistically significant heterogeneity that could not be explained by a priori defined subgroup analyses. We assume that differences in study designs and clinical heterogeneity in terms of study population, outcome assessment and health service resources may have resulted in differences in outcomes that could not be explained by the intervention per se. Furthermore, differences in vaccine effectiveness in case of mismatch and existing immunity if the circulating strain had been dominant for several seasons may have introduced heterogeneity across the included studies. Another major limitation was the potential risk of bias in the majority of studies, which further decreased the level of evidence. Finally, all but one study vaccinated children, thus, no generalisation to vaccination programmes in adults can be made, and the evidence is too limited to conclude in what setting(s) a significant herd effect may or may not be achieved. In summary, herd effects are assumed with influenza vaccine programmes, but there are few studies that quantify the herd effect of vaccination. We found low-level evidence supporting a herd effect of vaccination on influenza virus infection in contacts of vaccinated persons. Further rigorous studies are needed in order to better understand under which circumstances vaccination may prevent influenza and its complications in contacts.
  27 in total

Review 1.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.

Authors:  Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell
Journal:  Lancet       Date:  2011-11-10       Impact factor: 79.321

2.  Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2009-07-24

3.  Live attenuated and inactivated influenza vaccine in school-age children.

Authors:  W C Gruber; L H Taber; W P Glezen; R D Clover; T D Abell; R W Demmler; R B Couch
Journal:  Am J Dis Child       Date:  1990-05

4.  Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren.

Authors:  A S Monto; F M Davenport; J A Napier; T Francis
Journal:  J Infect Dis       Date:  1970 Jul-Aug       Impact factor: 5.226

5.  The Japanese experience with vaccinating schoolchildren against influenza.

Authors:  T A Reichert; N Sugaya; D S Fedson; W P Glezen; L Simonsen; M Tashiro
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

Review 6.  Leukocyte function in the aging immune system.

Authors:  Anjali Desai; Annabelle Grolleau-Julius; Raymond Yung
Journal:  J Leukoc Biol       Date:  2010-03-03       Impact factor: 4.962

7.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.

Authors:  Jonathan A C Sterne; Alex J Sutton; John P A Ioannidis; Norma Terrin; David R Jones; Joseph Lau; James Carpenter; Gerta Rücker; Roger M Harbord; Christopher H Schmid; Jennifer Tetzlaff; Jonathan J Deeks; Jaime Peters; Petra Macaskill; Guido Schwarzer; Sue Duval; Douglas G Altman; David Moher; Julian P T Higgins
Journal:  BMJ       Date:  2011-07-22

8.  Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses.

Authors:  R D Clover; S Crawford; W P Glezen; L H Taber; C C Matson; R B Couch
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

9.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

Authors:  L G Rudenko; A N Slepushkin; A S Monto; A P Kendal; E P Grigorieva; E P Burtseva; A R Rekstin; A L Beljaev; V E Bragina; N Cox
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

Authors:  Nicole E Basta; Dennis L Chao; M Elizabeth Halloran; Laura Matrajt; Ira M Longini
Journal:  Am J Epidemiol       Date:  2009-08-13       Impact factor: 4.897

View more
  8 in total

1.  [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra®].

Authors:  Sara Boccalini; Elena Pariani; Giovanna Elisa Calabrò; Chiara DE Waure; Donatella Panatto; Daniela Amicizia; Piero Luigi Lai; Caterina Rizzo; Emanuele Amodio; Francesco Vitale; Alessandra Casuccio; Maria Luisa DI Pietro; Cristina Galli; Laura Bubba; Laura Pellegrinelli; Leonardo Villani; Floriana D'Ambrosio; Marta Caminiti; Elisa Lorenzini; Paola Fioretti; Rosanna Tindara Micale; Davide Frumento; Elisa Cantova; Flavio Parente; Giacomo Trento; Sara Sottile; Andrea Pugliese; Massimiliano Alberto Biamonte; Duccio Giorgetti; Marco Menicacci; Antonio D'Anna; Claudia Ammoscato; Emanuele LA Gatta; Angela Bechini; Paolo Bonanni
Journal:  J Prev Med Hyg       Date:  2021-09-10

2.  Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial.

Authors:  Aldiouma Diallo; Ousmane M Diop; Doudou Diop; Mbayame Nd Niang; Jonathan D Sugimoto; Justin R Ortiz; El Hadji Abdourahmane Faye; Bou Diarra; Deborah Goudiaby; Kristen D C Lewis; Shannon L Emery; Sahar Z Zangeneh; Kathryn E Lafond; Cheikh Sokhna; M Elizabeth Halloran; Marc-Alain Widdowson; Kathleen M Neuzil; John C Victor
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

3.  Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011.

Authors:  Mbayame Nd Niang; Jonathan D Sugimoto; Aldiouma Diallo; Bou Diarra; Justin R Ortiz; Kristen D C Lewis; Kathryn E Lafond; M Elizabeth Halloran; Marc-Alain Widdowson; Kathleen M Neuzil; John C Victor
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

4.  Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Authors:  Melissa A Rolfes; Brendan Flannery; Jessie R Chung; Alissa O'Halloran; Shikha Garg; Edward A Belongia; Manjusha Gaglani; Richard K Zimmerman; Michael L Jackson; Arnold S Monto; Nisha B Alden; Evan Anderson; Nancy M Bennett; Laurie Billing; Seth Eckel; Pam Daily Kirley; Ruth Lynfield; Maya L Monroe; Melanie Spencer; Nancy Spina; H Keipp Talbot; Ann Thomas; Salina M Torres; Kimberly Yousey-Hindes; James A Singleton; Manish Patel; Carrie Reed; Alicia M Fry
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 20.999

5.  Effectiveness of Influenza Vaccines in the HIVE Household Cohort Over 8 Years: Is There Evidence of Indirect Protection?

Authors:  Ryan E Malosh; Joshua G Petrie; Amy Callear; Rachel Truscon; Emileigh Johnson; Richard Evans; Latifa Bazzi; Caroline Cheng; Mark S Thompson; Emily T Martin; Arnold S Monto
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

Review 6.  Influenza.

Authors:  Timothy M Uyeki; David S Hui; Maria Zambon; David E Wentworth; Arnold S Monto
Journal:  Lancet       Date:  2022-08-27       Impact factor: 202.731

7.  Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling.

Authors:  Jeanette Dawa; Gideon O Emukule; Edwine Barasa; Marc Alain Widdowson; Omu Anzala; Edwin van Leeuwen; Marc Baguelin; Sandra S Chaves; Rosalind M Eggo
Journal:  BMC Med       Date:  2020-08-20       Impact factor: 8.775

8.  Assessment of indirect protection from maternal influenza immunization among non-vaccinated household family members in a randomized controlled trial in Sarlahi, Nepal.

Authors:  Kira L Newman; Laveta M Stewart; Emily M Scott; James M Tielsch; Janet A Englund; Subarna K Khatry; Luke C Mullany; Steven C LeClerq; Laxman Shrestha; Jane M Kuypers; Helen Y Chu; Joanne Katz
Journal:  Vaccine       Date:  2020-08-17       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.